

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

**STA Degarelix for treating advanced hormone-
dependent prostate cancer**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

Consultees at the scoping stage noted that prostate cancer is more common in older men and African Caribbean men at increased risk compared with white men of the same age in the UK. NICE considers that this cannot be addressed within this technology appraisal because guidance on the use of degarelix would not be able to address this issue. Furthermore it is not expected that the preliminary recommendations in this technology appraisal would have any adverse impact in people with the mentioned characteristics.

Although the UK marketing authorisation is for ‘adult male patients’, it was agreed that the population in the appraisal should be amended to ‘adults’ because people who have undergone male to female gender reassignment can still develop prostate cancer.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these?

No other potential equality issues have been raised in the submissions, expert statements or academic report.

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

No other potential equality issues have been identified by the Committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No, none identified.

7. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

Yes. The summary table in the ACD notes the above.

Approved by Associate Director (name): Helen Knight

Date: 17/12/2013

Technology appraisals: Guidance development
Equality impact assessment for the single technology appraisal of degarelix for treating advanced hormone-dependent prostate cancer
Issue date: May 2014

Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No other potential equality issues have been raised during the consultation.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No changes have been made to the recommendations after consultation.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No changes have been made to the recommendations after consultation.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

No changes have been made to the recommendations after consultation.

5. Have the Committee's considerations of equality issues been

described in the final appraisal determination, and, if so, where?

Yes. The summary table in the FAD notes the above.

Approved by Programme Director (name): Meindert Boysen

Date: 23/04/2014